Biocon in talks with Bristol-Myers, Sanofi
The transaction, which could be valued at close to $1bn by potential suitors, includes a combination of upfront payments, milestone-linked payments and royalties on sales of the drug,
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.